Mapi - Pharma (Mapi - Pharma) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Mapi - Pharma's cash to debt ratio for the quarter that ended in Jun. 2015 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Mapi - Pharma could pay off its debt using the cash in hand for the quarter that ended in Jun. 2015.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Mapi - Pharma's Cash-to-Debt or its related term are showing as below:

MAPI's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.95
* Ranked among companies with meaningful Cash-to-Debt only.

Mapi - Pharma Cash-to-Debt Historical Data

The historical data trend for Mapi - Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mapi - Pharma Cash-to-Debt Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Cash-to-Debt

No Debt

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Cash-to-Debt	No Debt	No Debt	N/A	No Debt	No Debt

Competitive Comparison of Mapi - Pharma's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Cash-to-Debt falls into.

Mapi - Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Mapi - Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2014 is calculated as:

Mapi - Pharma had no debt ⁽¹⁾.

Mapi - Pharma's Cash to Debt Ratio for the quarter that ended in Jun. 2015 is calculated as:

Mapi - Pharma had no debt ⁽¹⁾.

Mapi - Pharma (NAS:MAPI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Mapi - Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.

Mapi - Pharma (Mapi - Pharma) Cash-to-Debt : No Debt (1) (As of Jun. 2015)